Meghan Podolsky

Can Prevention Save Money? This JAMA Forum discusses some key considerations for addressing the question of whether and when prevention interventions are worth the cost.

This right question about prevention: not whether it saves money, but whether it is worth the cost.

tinyurl.com/3ezrrvm4 @tuftscevr.bsky.social #health #prevention

07.04.2025 21:03 — 👍 5    🔁 3    💬 0    📌 0

2025 CEA Registry Remote Fellowship - Center for the Evaluation of Value and Risk in Health

Don't miss a chance to work with our renowned faculty! Applications for our 2025 CEA Registry Summer Fellowship close March 17th.

Learn more / apply today: cevr.tuftsmedicalcenter.org/news/2025-ce...

#internships #fellowship #healthecon

@pattysynnott.bsky.social @peterneumann11.bsky.social

17.02.2025 16:55 — 👍 3    🔁 3    💬 0    📌 0

Figure

Most viewed in the last 7 days from JAMA: This Medical News article discusses how the popularity of the antiobesity drugs #semaglutide and #tirzepatide may affect uptake of bariatric surgery.

https://ja.ma/4hLUcWf

08.02.2025 12:00 — 👍 11    🔁 3    💬 0    📌 1

Insurance coverage and type of employment shape inequities in access to semaglutide Developed initially to manage diabetes, glucagon-like peptide-1 (GLP-1) receptor agonists have skyrocketed in popularity since the US Food & Drug Administration first approved semaglutide (brand name Ozempic/Wegovy) for weight loss in 2021.

Insurance type and employment sector significantly influence access to semaglutide for weight management, highlighting disparities in healthcare access for obesity treatment. doi.org/g82s48

23.01.2025 01:02 — 👍 2    🔁 1    💬 0    📌 0

Insurance Coverage, Type of Employment Shape Inequities in Access to Semaglutide @busph.bsky.social bu.edu/sph/news/artic…
#obesity #healthequity #publichealth #glp1 #semaglutide

22.01.2025 17:40 — 👍 2    🔁 1    💬 0    📌 0

#obesity #glp1 #healthequity #semaglutide

@astokespop.bsky.social @khemp.bsky.social
5/

21.01.2025 16:33 — 👍 1    🔁 0    💬 0    📌 0

Structural factors may impact access to novel GLP-1/GIP RAs.

Future research should assess variations among populations (ex. Medicare, Medicaid) & incorporate add’l sociodemographic characteristics (race, ethnicity, income)
4/

21.01.2025 16:33 — 👍 1    🔁 0    💬 1    📌 0

The top features were included in a multivariable logistic regression model to quantify associations.

Key factors identified included sex, region, plan type, antidepressant use, obesity class, and employer industry.
3/

21.01.2025 16:33 — 👍 0    🔁 0    💬 1    📌 0

We used Marketscan Commercial data through 2022 to identify a cohort of pts with obesity without diabetes.

A random forest model was used to pinpoint the most impactful predictors of use, applying SHapley Additive exPlanations (SHAP) values.
2/

21.01.2025 16:33 — 👍 1    🔁 0    💬 1    📌 0

What factors affect semaglutide prescription?

In our study in @JAMANetworkOpen, we found that sex, insurance plan type, and use of certain medications were associated with semaglutide initiation.

jamanetwork.com/journals/jaman…
1/

21.01.2025 16:33 — 👍 1    🔁 0    💬 1    📌 0

Trends in Obesity Care Among US Adults, 2010–2021 : Medical Care th obesity care from 2010 to 2021 in the United States. Research Design: This multiyear cross-sectional study was conducted using Medical Expenditure Panel Survey (MEPS) data, covering respondents ...

New data on baseline levels of treatment for obesity pre-GLP1s - TLDR - very low journals.lww.com/lww-medicalc...

17.01.2025 19:19 — 👍 2    🔁 1    💬 0    📌 0